Table 5.
Univariable and multivariable analyses of factors associated with OS.
| Factor | Univariable | Multivariable | ||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Male | 1.27 (0.76–2.11) | 0.364 | ||
| Age ≥65 years | 2.08 (1.32–3.26) | 0.001 | 1.81 (1.13–2.88) | 0.013 |
| NSCLC histology | ||||
| Adenocarcinoma | 1 | |||
| Squamous | 1.02 (0.63–1.63) | 0.945 | ||
| Others | 0.85 (0.30–2.35) | 0.747 | ||
| ECOG ≥2 | 6.15 (3.06–12.37) | <0.001 | 4.92 (2.40–10.05) | <0.001 |
| No change in weight before treatment | 0.91 (0.70–1.18) | 0.469 | ||
| Smoking history | ||||
| No | 1 | 1 | ||
| Yes | 1.26 (0.78–2.02) | 0.345 | 1.31 (0.79–2.18) | 0.302 |
| Unknown | 2.60 (0.91–7.45) | 0.075 | 1.13 (0.37–3.48) | 0.829 |
| EGFR status | ||||
| Wild type | 1 | |||
| Mutant | 0.68 (0.27–1.70) | 0.408 | ||
| Unknown | 0.87 (0.51–1.48) | 0.599 | ||
| ALK status | ||||
| Wild type | 1 | |||
| Fusion | 0.00 (0.00–1.46E225) | 0.967 | ||
| Unknown | 0.76 (0.43–1.33) | 0.334 | ||
| Lines of immunotherapy | ||||
| First line | 1 | 1 | ||
| Second line | 1.62 (0.96–2.71) | 0.069 | 1.31 (0.74–2.32) | 0.360 |
| Third line and above | 1.19 (0.68–2.10) | 0.548 | 0.95 (0.46–1.97) | 0.883 |
| Type of drug, Anti-PD-L1 | 0.51 (0.28–0.94) | 0.03 | 0.61 (0.32–1.13) | 0.117 |
| Therapeutic modalities | ||||
| Single drug | 1 | 1 | ||
| Combined with chemotherapy | 0.68 (0.42–1.09) | 0.111 | 0.72 (0.43–1.19) | 0.197 |
| Combined with CTLA-4 | 0.97 (0.35–2.70) | 0.95 | 1.70 (0.54–5.40) | 0.367 |
| Others | 0.00 (0.00–3.45E267) | 0.97 | 0.00 (0.00–2.10E222) | 0.964 |
| irAE | 0.60 (0.37–0.97) | 0.036 | 0.76 (0.44–1.28) | 0.299 |
OS, overall survival; HR, hazard ratio; CI, confidence interval; irAE, immunotherapy-related adverse events; ECOG, Eastern Cooperative Oncology Group; EGFR, epithelial growth factor receptor; ALK, anaplastic lymphoma kinase; Bold values indicate P-values <0.05, considered statistically significant.